This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 120/10/835    most recent CIRCULATIONAHA.108.816884v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Levy, W. C. Articles by Bardy, G. H. PubMed PubMed Citation Articles by Levy, W. C. Articles by Bardy, G. H. Related Collections Health policy and outcome research Congestive Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs Related Articles

(Circulation. 2009;120:835-842.)
© 2009 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population

Wayne C. Levy, MD; Kerry L. Lee, PhD; Anne S. Hellkamp, MS; Jeanne E. Poole, MD; Dariush Mozaffarian, MD, DrPH; David T. Linker, MD; Aldo P. Maggioni, MD; Inder Anand, MD; Philip A. Poole-Wilson, MD; Daniel P. Fishbein, MD; George Johnson, BSEE; Jill Anderson, BSN, RN; Daniel B. Mark, MD, MPH; Gust H. Bardy, MD

From the University of Washington, Seattle (W.C.L., J.E.P., D.T.L., D.P.F.); Duke University Medical Center and Duke Clinical Research Institute, Durham, NC (K.L.L., A.S.H., D.B.M.); Harvard Medical School, Boston, Mass (D.M.); Italian Association of Hospital Cardiologists, Florence, Italy (A.P.M.); University of Minnesota, Minneapolis (I.A.); Imperial College School of Medicine, London, UK (P.A.P.-W.); and Seattle Institute of Cardiology Research, Seattle, Wash (G.J., J.A., G.H.B.).

Correspondence to Wayne C. Levy, MD, Division of Cardiology, University of Washington, Box 356422, 1959 NE Pacific St, Seattle, WA 98195. E-mail levywc{at}u.washington.edu

Received December 2, 2008; accepted July 1, 2009.

Background— Although implantable cardioverter-defibrillator (ICD) therapy reduces mortality in moderately symptomatic heart failure patients with an ejection fraction 35%, many such patients do not require ICD shocks over long-term follow-up.

Methods and Results— Using a modification of a previously validated risk prediction model based on routine clinical variables, we examined the relationship between baseline predicted mortality risk and the relative and absolute survival benefits of ICD treatment in the primary prevention Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). In the placebo arm, predicted 4-year mortality grouped into 5 equal-sized risk groups varied from 12% to 50% (c statistic=0.71), whereas the proportion of SCD in those same risk groups decreased from 52% to 24% of all deaths. ICD treatment decreased relative risk of SCD by 88% in the lowest-risk group versus 24% in the highest-risk group (P=0.009 for interaction) and decreased relative risk of total mortality by 54% in the lowest-risk group versus no benefit (2%) in the highest-risk group (P=0.014 for interaction). Absolute 4-year mortality reductions were 6.6%, 8.8%, 10.6%, 14.0%, and –4.9% across risk quintiles. In highest-risk patients (predicted annual mortality >20%), no benefit of ICD treatment was seen. Projected over each patient’s predicted lifespan, ICD treatment added 6.3, 4.1, 3.0, 1.9, and 0.2 additional years of life in the lowest- to highest-risk groups, respectively.

Conclusions— A clinical risk prediction model identified subsets of moderately symptomatic heart failure patients in SCD-HeFT in whom single-lead ICD therapy was of no benefit and other subsets in which benefit was substantial.

---

 

CLINICAL PERSPECTIVE

Related Articles:

Clinical Summaries
Circulation 2009 120: 823-824. [Extract] [Full Text]

Refining Patient Selection for Primary Prevention Implantable Cardioverter-Defibrillator Therapy: Reeling in a Net Cast Too Widely

Roderick Tung and Charles D. Swerdlow
Circulation 2009 120: 825-827. [Extract] [Full Text]

This article has been cited by other articles:

				R. Tung and C. D. Swerdlow Refining Patient Selection for Primary Prevention Implantable Cardioverter-Defibrillator Therapy: Reeling in a Net Cast Too Widely Circulation, September 8, 2009; 120(10): 825 - 827. [Full Text] [PDF]